Insulin, Long-ActingInsulinsInsulin, IsophaneHypoglycemic AgentsInsulin AspartHemoglobin A, GlycosylatedDiabetes Mellitus, Type 2Blood GlucoseDiabetes Mellitus, Type 1Insulin LisproDrug Administration ScheduleClinical Trials, Phase III as TopicInsulinHypoglycemiaVenomsInsulin, Regular, HumanTreatment OutcomeInjections, SubcutaneousSulfonylurea CompoundsMetforminDrug SubstitutionInfusions, SubcutaneousDrug Therapy, CombinationBlood Glucose Self-MonitoringChronotherapyC-PeptideRandomized Controlled Trials as TopicIsoindolesModels, EconomicCross-Over StudiesInsulin Infusion SystemsRibonucleoprotein, U1 Small NuclearPostprandial PeriodGlucose Clamp TechniqueInsulin AntibodiesFastingDiabetic KetoacidosisDose-Response Relationship, DrugCircadian RhythmRibonucleoprotein, U4-U6 Small NuclearInjectionsDipeptidyl-Peptidase IV InhibitorsQuality-Adjusted Life YearsHyperglycemiaAdministration, OralMonitoring, AmbulatoryMulticenter Studies as TopicEpidural SpaceBody WeightWeight GainReceptor, IGF Type 1Double-Blind MethodDelayed-Action PreparationsPeptidesNational Health ProgramsNeoplasmsIndividualityRibonucleoprotein, U5 Small NuclearDiabetes MellitusGlucagon-Like Peptide 1Retrospective StudiesPatient SatisfactionRats, ZuckerDatabases, FactualThiazolidinedionesReceptor, InsulinGlycemic IndexDrug CostsProbabilityCost-Benefit AnalysisJapanBiotransformationIncidenceBody Mass IndexFranceMaternal-Fetal ExchangeTime FactorsDiabetes ComplicationsGermanyAsian Continental Ancestry GroupImmunoassayProspective StudiesReproducibility of ResultsPatient ComplianceEthnic Groups